ANDA 91129, held by Watson Laboratories. Losartan Potassium.
As of Nov 21, 2026, ANDA 91129 (Losartan Potassium), held by Watson Laboratories, was first approved by FDA on Oct 6, 2010, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2010 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Sep 25, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 13, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 3, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 20, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 27, 2010 | Supplement 1Labeling | Approved | None posted |
| Oct 6, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters